EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

COVID-19 vaccine-induced immune thrombotic thrombocytopenia

Malay Sarkar, Irappa V Madabhavi, Pham Nguyen Quy, Manjunath B Govindagoudar

Annals of Thoracic Medicine · 2022-01 · 17 (1) · 1-13

DOI: 10.4103/atm.atm_404_21 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Thoracic Medicine, 2022-01. Verfasst von Malay Sarkar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus responsible for the pandemic coronavirus disease 19 (COVID-19). It has significant impact on human health and public safety along with negative social and economic consequences. Vaccination against SARS-CoV-2 is likely the most effective approach to sustainably control the global COVID-19 pandemic. Vaccination is highly effective in reducing the risk of severe COVID-19 disease. Mass-scale vaccination will help us in attaining herd immunity and will lessen the negative impact of the disease on public health, social and economic conditions. The present pandemic stimulated the development of several effective vaccines based on different platforms. Although the vaccine is safe and efficacious, rare cases of thrombosis and thrombocytopenia following the use of vaccination with the ChAdOx1 CoV-19 vaccine (AstraZeneca, University of Oxford, and Serum Institute of India) or the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) have been reported globally. This review focussed on the definition, epidemiology, pathogenesis, clinical features, diagnosis, and management of vaccine associated thrombosis.

Schlagwörter

Stichwörter der Autor:innen

COVID-19 vaccineheparin-induced thrombocytopeniaplatelet factor-4thrombosisvaccine-induced immune thrombotic thrombocytopenia

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.
  • Department of Medical and Pediatric Oncology, Kerudi Cancer Hospital, Bagalkot, Karnataka, India.
  • Department of Medical Oncology, J N Medical College, Belagavi, Karnataka, India.
  • Department of Medical Oncology, Kyoto Miniren Central Hospita, Ukyoku, Kyoto, Japan.
  • Department of Pulmonary and Critical Care, Pt B. D. Sharma, Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India.

Zitieren

APA

Sarkar, M., Madabhavi, I. V., Quy, P. N., & Govindagoudar, M. B. (2022). COVID-19 vaccine-induced immune thrombotic thrombocytopenia. Annals of Thoracic Medicine, 17(1), 1-13. https://doi.org/10.4103/atm.atm_404_21

Vancouver

Sarkar M, Madabhavi IV, Quy PN, Govindagoudar MB. COVID-19 vaccine-induced immune thrombotic thrombocytopenia. Annals of Thoracic Medicine. 2022;17(1):1-13. doi:10.4103/atm.atm_404_21

BibTeX
@article{Sarkar2022,
  author = {Sarkar, Malay and Madabhavi, Irappa V and Quy, Pham Nguyen and Govindagoudar, Manjunath B},
  title = {COVID-19 vaccine-induced immune thrombotic thrombocytopenia},
  journal = {Annals of Thoracic Medicine},
  year = {2022},
  volume = {17},
  number = {1},
  pages = {1--13},
  doi = {10.4103/atm.atm_404_21}
}
Kostenlos starten →